Microbix Biosystems Inc.
MBXBF · OTC
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | -0.00 | 10.71 | -5.54 |
| FCF Yield | -2.41% | 5.22% | -4.88% | 2.06% |
| EV / EBITDA | 72.71 | 6.48 | 19.55 | 18.68 |
| Quality | ||||
| ROIC | -4.41% | 10.72% | -8.67% | 8.39% |
| Gross Margin | 53.02% | 60.61% | 45.30% | 58.32% |
| Cash Conversion Ratio | 0.04 | 1.24 | 27.72 | 1.94 |
| Growth | ||||
| Revenue 3-Year CAGR | -6.86% | 10.01% | -3.87% | 21.92% |
| Free Cash Flow Growth | -125.81% | 215.64% | -246.63% | 79.01% |
| Safety | ||||
| Net Debt / EBITDA | -12.47 | -1.06 | -2.54 | -2.30 |
| Interest Coverage | -1.66 | 4.24 | -3.26 | 3.26 |
| Efficiency | ||||
| Inventory Turnover | 0.95 | 1.55 | 1.57 | 1.50 |
| Cash Conversion Cycle | 333.36 | 198.95 | 239.41 | 217.17 |